BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 29122990)

  • 21. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
    Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
    Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
    Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Another step forward in the 20-year history of
    Giudice ID; Foà R
    Haematologica; 2019 Feb; 104(2):219-221. PubMed ID: 30705114
    [No Abstract]   [Full Text] [Related]  

  • 25. Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?
    Rozovski U; Keating MJ; Estrov Z
    Acta Haematol; 2018; 140(1):51-54. PubMed ID: 30114695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
    Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
    Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.
    Heerema NA; Muthusamy N; Zhao Q; Ruppert AS; Breidenbach H; Andritsos LA; Grever MR; Maddocks KJ; Woyach J; Awan F; Long M; Gordon A; Coombes C; Byrd JC
    Haematologica; 2021 Jun; 106(6):1608-1615. PubMed ID: 32414849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
    Bhoi S; Baliakas P; Cortese D; Mattsson M; Engvall M; Smedby KE; Juliusson G; Sutton LA; Mansouri L
    Haematologica; 2016 Feb; 101(2):e63-5. PubMed ID: 26589911
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
    Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High CXCR3 on Leukemic Cells Distinguishes
    Manukyan G; Papajik T; Mikulkova Z; Urbanova R; Kraiczova VS; Savara J; Kudelka M; Turcsanyi P; Kriegova E
    J Immunol Res; 2020; 2020():7084268. PubMed ID: 32802894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telomeres and prognosis in patients with chronic lymphocytic leukaemia.
    Sellmann L; de Beer D; Bartels M; Opalka B; Nückel H; Dührsen U; Dürig J; Seifert M; Siemer D; Küppers R; Baerlocher GM; Röth A
    Int J Hematol; 2011 Jan; 93(1):74-82. PubMed ID: 21203871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
    Hamblin TJ; Davis Z; Gardiner A; Oscier DG; Stevenson FK
    Blood; 1999 Sep; 94(6):1848-54. PubMed ID: 10477713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups.
    MacIntyre DA; Jiménez B; Lewintre EJ; Martín CR; Schäfer H; Ballesteros CG; Mayans JR; Spraul M; García-Conde J; Pineda-Lucena A
    Leukemia; 2010 Apr; 24(4):788-97. PubMed ID: 20090781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.
    Patten PE; Chu CC; Albesiano E; Damle RN; Yan XJ; Kim D; Zhang L; Magli AR; Barrientos J; Kolitz JE; Allen SL; Rai KR; Roa S; Mongini PK; MacCarthy T; Scharff MD; Chiorazzi N
    Blood; 2012 Dec; 120(24):4802-11. PubMed ID: 23071276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia.
    Rani L; Mathur N; Gogia A; Vishnubhatla S; Kumar L; Sharma A; Dube D; Kaur P; Gupta R
    Leuk Lymphoma; 2016 Oct; 57(10):2389-400. PubMed ID: 26942309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.
    Eagle GL; Zhuang J; Jenkins RE; Till KJ; Jithesh PV; Lin K; Johnson GG; Oates M; Park K; Kitteringham NR; Pettitt AR
    Mol Cell Proteomics; 2015 Apr; 14(4):933-45. PubMed ID: 25645933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
    Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
    Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene.
    Qin SC; Xia Y; Miao Y; Zhu HY; Wu JZ; Fan L; Li JY; Xu W; Qiao C
    Blood Cancer J; 2017 Dec; 7(12):651. PubMed ID: 29242635
    [No Abstract]   [Full Text] [Related]  

  • 40. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.
    Del Giudice I; Chiaretti S; Santangelo S; Tavolaro S; Peragine N; Marinelli M; Ilari C; Raponi S; Messina M; Nanni M; Mauro FR; Piciocchi A; Bontempi K; Rossi D; Gaidano G; Guarini A; Foà R
    Am J Hematol; 2014 Jan; 89(1):74-82. PubMed ID: 24030933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.